SAB Biotherapeutics Shows Data at FOCIS 2026 Meeting

SAB Biotherapeutics (SABS) presented at the FOCIS 2026 Annual Meeting on Wednesday, publishing a slide deck that covered its immunotherapy pipeline. The company, which develops human polyclonal antibodies using its Transchromosomic (Tc) Bovine platform, did not disclose specific data from the presentation beyond the deck itself.

FOCIS, the Federation of Clinical Immunology Societies, is a major gathering for immunology researchers and drug developers. A slot at the meeting signals that SAB’s programs – focused on infectious diseases, autoimmune conditions, and transplant medicine – have cleared peer review for public discussion.

SAB’s platform produces fully human antibodies without the need for human donors or hybridoma cell lines. The company has advanced candidates against COVID-19, influenza, and organ transplant rejection into clinical trials. The FOCIS deck likely updated those programs, though the company has not released topline results from any ongoing study.

The slide deck is available on SAB’s investor relations page.